Cellular Protein FGD3 Boosts Breast Cancer Chemotherapy and Immunotherapy, Study Finds

Cellular protein FGD3 boosts breast cancer chemotherapy and immunotherapy, study finds

A naturally-occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report. The protein, FGD3, contributes to the rupture of cancer cells disrupted by these drugs, boosting their effectiveness and enhancing anticancer immunotherapies.

Breast Cancer Biomarker Predicts Efficacy of Chemo and Immunotherapy

A new study published in the Journal of Experimental & Clinical Cancer Research has identified the FGD3 protein as a promising predictive biomarker that potentially enhances the efficacy of chemotherapy and other cancer treatments that induce lytic cell death.  “We found, with all types of chemotherapy and all classes of breast cancer, there’s a very high correlation between the level of FGD3 and whether the patient responds favorably to chemoth…

Protein FGD3 Found to Boost Effectiveness of Breast Cancer Treatments

Researchers have identified a naturally occurring prote […] The post Protein FGD3 Found to Boost Effectiveness of Breast Cancer Treatments first appeared on GeneOnline News. The post Protein FGD3 Found to Boost Effectiveness of Breast Cancer Treatments appeared first on GeneOnline News.